What is HC Wainwright’s Forecast for MDGL Q1 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Investment analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings per share of ($2.83) for the quarter, down from their previous estimate of ($2.10). HC Wainwright currently has a “Buy” rating and a $405.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q2 2025 earnings at ($2.14) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($7.82) EPS, FY2026 earnings at $9.85 EPS, FY2027 earnings at $31.36 EPS, FY2028 earnings at $52.07 EPS and FY2029 earnings at $87.27 EPS.

Several other research firms have also weighed in on MDGL. JMP Securities reaffirmed a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. B. Riley raised Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and upped their target price for the company from $236.00 to $422.00 in a report on Thursday, February 27th. Citigroup lifted their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $375.75.

Madrigal Pharmaceuticals Stock Up 2.5 %

MDGL opened at $321.32 on Monday. The stock’s fifty day moving average is $323.17 and its 200-day moving average is $286.30. Madrigal Pharmaceuticals has a one year low of $189.00 and a one year high of $377.46. The company has a market capitalization of $7.09 billion, a PE ratio of -12.81 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.32) by $1.61. The business had revenue of $103.32 million for the quarter, compared to analyst estimates of $97.81 million.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, insider Carole Huntsman sold 347 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $116,328.28. Following the completion of the transaction, the insider now directly owns 10,438 shares of the company’s stock, valued at $3,499,235.12. This trade represents a 3.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $461,789.49. Following the completion of the transaction, the chief marketing officer now owns 457,310 shares of the company’s stock, valued at approximately $125,033,127.10. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,787 shares of company stock valued at $7,351,029 in the last 90 days. 22.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth $141,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Madrigal Pharmaceuticals by 23.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 27,538 shares of the biopharmaceutical company’s stock valued at $8,497,000 after buying an additional 5,182 shares during the period. Woodline Partners LP increased its position in shares of Madrigal Pharmaceuticals by 110.2% in the 4th quarter. Woodline Partners LP now owns 309,117 shares of the biopharmaceutical company’s stock valued at $95,384,000 after buying an additional 162,027 shares in the last quarter. Vestal Point Capital LP raised its stake in Madrigal Pharmaceuticals by 216.7% during the 4th quarter. Vestal Point Capital LP now owns 95,000 shares of the biopharmaceutical company’s stock worth $29,314,000 after buying an additional 65,000 shares during the period. Finally, Soleus Capital Management L.P. bought a new position in Madrigal Pharmaceuticals during the fourth quarter worth about $3,363,000. Institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.